Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
2
50%
Ph phase_4
1
25%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 41 (25.0%)

Trials by Status

not_yet_recruiting125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_2

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

NCT07239440
completedphase_4

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

NCT05743907
completedphase_1

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)

NCT04938752
completedphase_1

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

NCT04473417

Clinical Trials (4)

Showing 4 of 4 trials
NCT07239440Phase 2

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Not Yet Recruiting
NCT05743907Phase 4

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

Completed
NCT04938752Phase 1

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)

Completed
NCT04473417Phase 1

Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4